AU2529697A - Oligonucleotides targeted to angiotensinogen mrna - Google Patents
Oligonucleotides targeted to angiotensinogen mrnaInfo
- Publication number
- AU2529697A AU2529697A AU25296/97A AU2529697A AU2529697A AU 2529697 A AU2529697 A AU 2529697A AU 25296/97 A AU25296/97 A AU 25296/97A AU 2529697 A AU2529697 A AU 2529697A AU 2529697 A AU2529697 A AU 2529697A
- Authority
- AU
- Australia
- Prior art keywords
- oligonucleotide
- mrna
- angiotensinogen
- antisense
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004881 Angiotensinogen Human genes 0.000 title claims description 114
- 108090001067 Angiotensinogen Proteins 0.000 title claims description 114
- 108091034117 Oligonucleotide Proteins 0.000 title claims description 85
- 108020004999 messenger RNA Proteins 0.000 title claims description 69
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title description 20
- 239000002502 liposome Substances 0.000 claims description 89
- 230000000692 anti-sense effect Effects 0.000 claims description 65
- 150000001875 compounds Chemical class 0.000 claims description 56
- 230000014509 gene expression Effects 0.000 claims description 42
- 206010020772 Hypertension Diseases 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 125000002091 cationic group Chemical group 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 108091081021 Sense strand Proteins 0.000 claims description 13
- 101000732617 Homo sapiens Angiotensinogen Proteins 0.000 claims description 12
- 239000013603 viral vector Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108091081024 Start codon Proteins 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 229930024421 Adenine Natural products 0.000 claims 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 34
- 238000011282 treatment Methods 0.000 description 27
- 230000036772 blood pressure Effects 0.000 description 24
- 230000007423 decrease Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 230000027455 binding Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 239000000074 antisense oligonucleotide Substances 0.000 description 13
- 238000012230 antisense oligonucleotides Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 230000001631 hypertensive effect Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 238000000636 Northern blotting Methods 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 8
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000004700 cellular uptake Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 230000004872 arterial blood pressure Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- -1 elixir Substances 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000005862 Angiotensin II Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000629622 Homo sapiens Serine-pyruvate aminotransferase Proteins 0.000 description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 101150030170 Paat gene Proteins 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 102000049538 human AGT Human genes 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000006461 physiological response Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KYNFOMQIXZUKRK-UHFFFAOYSA-N 2,2'-dithiodiethanol Chemical compound OCCSSCCO KYNFOMQIXZUKRK-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- FPKBIYKAYFGTKG-UHFFFAOYSA-N [5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(6-aminopurin-9-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl] [3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methyl hydrogen phosphate Chemical compound Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O FPKBIYKAYFGTKG-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000012977 invasive surgical procedure Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000002461 renin inhibitor Substances 0.000 description 2
- 229940086526 renin-inhibitors Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 229910001868 water Inorganic materials 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 101150092712 72 gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229940123073 Angiotensin antagonist Drugs 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 101000796258 Rattus norvegicus Angiotensinogen Proteins 0.000 description 1
- 101000629625 Rattus norvegicus Serine-pyruvate aminotransferase, mitochondrial Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000010441 alabaster Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002369 angiotensin antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 108010084541 asialoorosomucoid Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZIIWDYUUDCODMT-UHFFFAOYSA-N benzene;5-sulfonyltetrazole Chemical compound C1=CC=CC=C1.O=S(=O)=C1N=NN=N1 ZIIWDYUUDCODMT-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000245 dipsogenic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008290 endocytic mechanism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- LSMZHPCHKDMYMQ-UHFFFAOYSA-N n-[chloro(methyl)phosphoryl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(C)(Cl)=O LSMZHPCHKDMYMQ-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000013300 spontaneous hypertensive rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WZMPOCLULGAHJR-UHFFFAOYSA-N thiophen-2-ol Chemical compound OC1=CC=CS1 WZMPOCLULGAHJR-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3511—Conjugate intercalating or cleaving agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA
Background Of The Invention
Technical Field
This invention relates to compositions and methods which are useful for reducing hypertension in humans. More particularly, it relates to oligonucleotide compounds capable of binding to angiotensinogen mRNA to inhibit expression of angiotensinogen, and thereby, essential hypertension.
Background Art
Angiotensinogen (AGT) , which is produced largely by the liver, is the substrate for the protein remn, produced by the kidneys. The action of remn on angiotensinogen results in the formation of the decapeptide angiotensm I. Angiotensm I is further converted to the octapeptide angiotensm II, through the action of angiotensm converting enzyme (ACE) as it circulates through the vasculature. Angiotensm II is a potent vasoconstrictor and regulator of blood pressure and volume homeostasis. An overactive rerun angiotensm
system (RAS) has been implicated in the development and maintenance of essential hypertension and related forms of hypertension in humans which affects approximately 40 million adults in the United States. Through the inhibition of angiotensinogen the production of angiotensin II can be inhibited, subsequently decreasing hypertensive blood pressures.
Genetic variants of AGT have been associated with elevated plasma AGT levels in hypertensive patients and a predisposition to preeclampsia or atherosclerosis m specific populations (Jeunmatre, X., et al.. , Cell 71 (1) :169-80, 1992; Hixon, J. E. and Powers, P. K. , Human Genet . 96:110-112, 1995) . The RAS can be inhibited by several mechanisms, which mclude ACE inhibitors, renin inhibitors and angiotensin antagonists but as yet there has been no specific inhibitor of AGT. The production of AGT is controlled mainly by hormones that act upon gene transcription and affect the concentration of the mRNA in tissues. The most important role played by hormones in the regulation of AGT may be to maintain its synthesis and constitutive secretion during its rapid consumption by high levels of renin. Hepatic AGT is regulated mainly at the transcriptional level in hepatocytes, by hormones acting at the genomic level such as steroids, thyroid hormones, glucocorticoids and inflammatory cytokines via activation of DNA binding proteins that interact with the appropriate response elements and multi-hormone response sites like the hormone mducible enhancer unit (HIEU) at nucleotides -615 to -440 upstream of the major transcription start site (Peters, J. , supra, 1995; Brashier, A. R. , ej: a . , Kidney International , 46:1564- 1566, 1994) .
A large number of antihypertensive agents are commercially available, however most have severe side effects which generally require the action of a second
group of agents. This, in combination with the nature of the disease, tends to result in poor patient compliance. A number of renin angiotensm system inhibitors presently under use mclude: renin inhibitors, angiotensm converting enzyme inhibitors, and angiotens receptor blockers. These agents also lack specificity, have unwanted side effects, require frequent dosing regimens, and do not completely prevent the formation of angiotensm II. An alternative approach has been proposed to reduce hypertension. A number of researchers have developed antisense sequences for the inhibition of renin- angiotensm system components.
Antisense oligodeoxynucleotides have been used to successfully inhibit prote synthesis m a number of biological systems (Yakubov, L. , e_t a_l . , Proc. Natl . Acad . Sci . USA 86:6454-6458, 1989; Wahlstedt, D., et al., Science 259:528-531, 1993; Wahlstedt, D., et al., Na ture 363:260-263, 1993; Wielbo, D., e^ a ., Hypertension 25:314-319, 1995) . This paradigm of gene regulation has many potential therapeutic applications and is currently being developed for application as anticancer, antianxiety, antiviral and antiparasitic agents. Antisense regulation or attenuation of protem synthesis can be applied to any candidate gene with known molecular sequence.
Antisense molecules are short strands of DNA or RNA, usually 12-18 bases in length which are synthesized to complement a target region of a candidate gene. The antisense molecule binds to its complementary region and via a number of mechanisms inhibits or attenuates gene expression (Helene, C. C. and Toulme, J. J. , Biochemica et Biophysica Acta 1049:99-125, 1990) .
Advances m understanding the function, metabolism and structure of these molecules has lead to the development of antisense molecules with enhanced nuclease
resistance and increased specificity, selectivity and potency (Crooke, S. T. , FASEB J. 7:533-539, 1993) . Phosphorothioated ASODN are modified phosphodiester oligonucleotides where one of the non-bridged oxygen atoms of the internucleotide linkage has been replaced with a sulfur. Fully thioated antisense molecules are more resistant to nucleases but also exhibit several non sequence-specific effects m doses generally greater than 1 μm (Wagner, R. W., JVature 372:333-335, 1994) . Phosphorothioation also stimulates the activity of
RNase H. This enzyme recognizes the DNA-mRNA duplex as a substrate and cleaves the mRNA portion of the duplex, freeing the DNA antisense molecule to bind to other mRNA strands promoting a type of catalytic effect (Helene, C. C and Toulme, J. J., supra. 1990; Boiziau, C, et. al . , Biochemi cal Soci ety Transactions 20 -. 164 - 161, 1992) .
We and others have utilized the concept of antisense technology as a physiological tool to provide information on cardiovascular function and hypertension. Sakai and Meng demonstrated that angiotensm II type 1 (ATI) receptor antisense oligonucleotides inhibit dipsogenic responses to Angll (Sakai, R. R., e_t al . , J. Neurochem . 62:2053-2056, 1994; Meng, H., et al., .Regulatory Peptides 54:543-551, 1994) and Morishita and coworkers successfully used antisense targeted to proliferating cell nuclear antigens to inhibit neomtima formation after balloon catheter angioplasty (Morishita, R. , et. aJL., Proc . Natl . Acad . Sci . USA 90 (18) : 8474-8, 1993) .
Gyurko was able to show decreases in blood pressure after central administration of ASODN targeted to the ATI receptor (Gyurko, R., et. a_l . , Regula tory Peptides 49:16^ 174, 1993) and similar effects were observed when Wielbo targeted central AGT (Wielbo, D. , et al., supra, 1995) . Recently, Tomita was able to decrease blood pressure in the SHR using three contiguous antisense oligonucleotide sequences to target peripheral AGT and also showed
decreases in AGT mRNA (Tomita, N. , et. al. , Hypertension 24(3) :65, 397, 1994; Tomita, N., et al., Hypertension 26:131-136, 1995) . Wielbo, et a . also decreased hypertensive blood pressures in a rat model using a liposome encapsulated 18-mer ODN sequence but no changes in mRNA were observed (Wielbo, D., et aJL. , Hypertension 28:147-151, 1996) .
N. Tomita, et al . , 26 Hypertension 131-136 (1995) demonstrated that the administration of an antisense molecule targeted to the exon/intron junctions of nascent mRNA transiently decreases blood pressure in a rat model of hypertension. These antisense molecules were administered directly into the hepatic portal vein via a liposomal delivery mechanism incorporating a viral antigen to facilitate hepatic uptake. This research group demonstrated a decrease in blood pressures, with subsequent decreases in peripheral angiotensinogen and angiotensinogen mRNA. Note that no informaiton was given regarding dosage rates or number of injections. However, dose response studies were carried out using up to
15μMol/L to get significant decreases in AGT. This data was represented as ratios probably due to non-specific effects observed by control oligos at such high doses.
One drawback of the Tomita, e_t_ a . method is that an invasive surgical procedure is required to administer the liposomes via the hepatic portal vein. Another drawback to the injection of antisense molecules directly into the liver (at the volumes used by Tomita) is the risk of damaging liver tissue. Also, viral antigen modification must be done to facilitate hepatic uptake.
Unfortunately, the art has not yet developed an approach which avoids the forgoing problems. Thus, the need exists for effective ASODN hypertension treatment compositions which avoid toxic side effects and are efficacious in small dosages, and a method which does not require invasive surgical administration techniques.
Disclosure Of The Invention
The mvention resides in the discovery that AGT expression can be inhibited m humans by administration of oligonucleotide compounds of Formula I:
in which: each X independently is 0, S, or Cx 4 alkyl ; each B independently is adenme, guanme, cytosme, or thymme selected such that the oligonucleotide is capable of binding to the sense mRNA strand coding for human angiotensinogen to thereby inhibit the translation thereof; each R independently is H or C1-4 alkyl or P(0) (0) -substituted acπdme; each Y independently is H or OH; and n is 8 to 23. The oligonucleotide compound of Formula I may also be a pharmaceutically acceptable salt or hydrate thereof. Preferably, B is selected such that the oligonucleotide is antisense to the sense mRNA strand for human angiotensinogen. More preferably, B is selected such that the oligonucleotide is capable of binding to the mRNA base region encompassing the AUG initiation codon.
Another aspect of the invention provides a pharmaceutical composition useful for inhibiting expression of angiotensinogen comprising a pharmaceutical carrier and oligonucleotides of the above kind. The pharmaceutical carrier may be a liposome, viral vector, or protem conjugate formulation.
Another aspect of the mvention provides a method for treating hypertension m a human comprising administering to a subject an effective amount of oligonucleotides or compositions of the above kind.
The objects of the present invention therefore mclude providing compounds, compositions and methods of the above kind that :
(a) avoid toxic side effects; (b) avoid invasive surgical procedures;
(c) are effective in small dosages; and
(d) specifically target angiotensinogen mRNA. These and still other objects and advantages of the present invention will be apparent from the description below.
Brief Description Of The Drawings
Fig. 1 is a bar graph depicting the percent expression of angiotensinogen using one antisense oligonucleotide of the present invention; Figs. 2a and 2b are micrographs of rat liver tissue one hour after injection of unencapsulated antisense oligonucleotide and liposome encapsulated oligonucleotide, respectively;
Fig. 3 is a bar graph depicting the change m mean arterial pressure after treating spontaneously hypertensive rats with liposome encapsulated antisense oligonucleotide and control compositions;
Fig. 4 is a bar graph depicting the level of plasma angiotens II of spontaneously hypertensive rats after
treatmg them with liposome encapsulated antisense oligonucleotide and control compositions;
Fig. 5 is a bar graph depicting the level of plasma angiotensinogen of spontaneously hypertensive rats after treating them with liposome encapsulated antisense oligonucleotide and control compositions;
Fig. 6 is a graph showing comparative data using a viral vector delivery system;
Fig. 7a shows a Northern blot hybridization for AGT and the control gene cathepsm D;
Fig. 7b is a bar graph showmg the relative intensity of AGT mRNA expression after treatment compared to angiotensinogen expression in untreated control cells;
Fig. 8 is a bar graph showmg the effect of cationic liposome conjugated ASODN on angiotensinogen production;
Fig. 9a shows a Northern blot hybridization for AGT and the control gene cathepsm D;
Fig. 9b is a bar graph showing the relative expression of AGT mRNA compared to control treated samples; and
Fig. 10 is a bar graph showmg the dose dependent decreases in angiotensinogen protem after cationic liposomal delivery of ASODN.
Best Modes For Carrying Out The Invention The native DNA segment coding for angiotensinogen
(AGT) , as all such mammalian DNA strands, has two strands: a sense strand and an antisense strand held together by hydrogen bonding. The messenger RNA coding for AGT has the same nucleotide sequence as the sense DNA strand except that the DNA thymidme is replaced by undine . Thus, synthetic antisense nucleotide sequences should bind with tne DNA and RNA coding for AGT.
The oligonucleotide compounds of the mvention bind to the messenger RNA coding for human AGT thereby inhibiting expression of this protem. Preferred
compounds of the invention are antisense to the sense DNA sequence coding for human AGT as shown in Fig. 2 of Fukamizu, et al. 265 J^ Biol. Chem. 7576-7582 (1990) . Especially preferred oligonucleotide compounds are those in which B of Formula I is selected such that the base sequence of the oligonucleotide is 5' -CTCGCTTCCGCATACCCT-3' (SEQ ID N0:1) .
In the specification and claims, the letters, A, G, C, T, and U respectively indicate nucleotides in which the nucleoside is Adenosine (Ade) , Guanosine (Gua) , Cytidine (Cyt) , Thymidine (Thy) , and Uridine (Ura) . As used in the specification and claims, compounds that are antisense to the AGT DNA or mRNA sense strand are compounds which have a nucleoside sequence complementary to the sense strand. Table 1 shows the four possible sense strand nucleosides and their complements present in an antisense compound.
TABLE 1
Sense Antisense
Ade Thy Gua Cyt Cyt Gua Thy Ade Ura Ade
It will be understood by those skilled in the art that the present invention broadly includes oligonucleotide compounds which are capable of binding to the sense mRNA strand coding for angiotensinogen. Thus, the invention includes compounds which are not strictly antisense: the compounds may have some non-complementary bases provided such compounds have sufficient binding affinity for angiotensinogen mRNA to inhibit expression. The compounds of Formula I also differ from native DNA in that some or all of the phosphates in the nucleotides are replaced by phosphorothioates (X=S) or
methylphosphonates (X=CH3) or other Cl 4 alkylphosphonates . The compounds of Formula I optionally may be further differentiated from native DNA by replacing one or both of the free hydroxy groups of the sense molecule with λ 4 alkoxy groups (R=Cj 4 alkoxy) . As used herein, Cα 4 alkyl means a branched or unbranched hydrocarbon having 1 to 4 carbon atoms .
Formula I compounds also may be substituted at the 3' and/or 5' ends by a substituted acridme derivative. As used herein, "substituted acridme" means any acridme derivative capable of intercalating nucleotide strands such as DNA. Preferred substituted acrid es are 2- methoxy-6-chloro-9-pentylammoacrιdme, N- (6-chloro-2- methoxyacndmyl) -O-methoxydiisopropylammophosphmyl-3- ammopropanol, and N- (6-chloro-2-methoxyacridmyl) -O- methoxydιιsopropylammophosphmyl-5-ammopentanol . Other suitable acridme derivatives are readily apparent to persons skilled m the art. Additionally, as used herein "P(0) (0) -substituted acridme" means a phosphate covalently linked to a substitute acridme.
Formula I compounds also may mclude ribozyme sequences inserted into their nucleotide sequence. The ribozyme sequences are inserted mto Formula I compounds such that they are immediately preceded by AUC, UUC, GUA, GUU, GUC, or, preferably, CUC. The ribozyme sequence is any sequence which can be inserted and causes self- cleavage of messenger RNA. The sequence CUG AUG AGU CCG UGA CGA A is preferred. Other such sequences can be prepared as described by Haseloff and Gerlach, 334 Nature 585-591 (1988) .
The compounds of Formula I have about 10 to 25 nucleotides. As used herein, the term "nucleotides" includes nucleotides which the phosphate moiety is replaced by phosphorothioate or alkylphosphonate and the nucleotides may be substituted by substituted acridmes. Preferred Formula I compounds have 13 to 22 nucleotides.
More preferred are compounds havmg 16 to 20 nucleotides. Most preferred are compounds havmg 18 nucleotides. Compounds havmg fewer than 10 nucleotides are less desirable because they generally have less specificity and compounds having greater than 25 nucleotides are less desirable because their physical size and charge will attenuate the crossing of the lipophilic cell membrane. Thus, they are less likely to enter cells.
Although Formula I compounds that are antisense to human AGT mRNA are preferred, Formula I includes nucleotide compounds which lack a complement for each nucleotide in a segment of the mRNA sense strand provided such compounds have sufficient binding affinity for human AGT mRNA to inhibit expression. The procedures of Examples 1 and 5 are useful for screening whether specific oligonucleotides of the present invention are effective in inhibiting angiotensinogen expression.
Formula I compounds in which R is H are preferred. R, however, can be Cj 4 alkyl provided the resulting compounds retains sufficient binding affinity for the AGT mRNA sense strand to inhibit expression of AGT.
Formula I compounds in which at least one X is S are prepared by the following published procedures: W.J. Stec, e_t al. , 106 J^ Am. Che . Soc . 6077-6079 (1984) ; S.P. Adams, et al., 105 J_ Am. Chem. Soc. 661 (1983) ;
M.H. Caruthers, et. al. , 4 Genetic Engineering 1, Settlow, J. Hollander. A. Eds; Plenum Press: New York (1982) ; M.S. Broido, et. aJL . , 119 Biochem. Biophys. Res . Commun. 663 (1984) . The reaction scheme described m these published procedures is conducted on a solid support.
The reaction scheme involves lH-tetrazole-catalyzed coupling of phosphoramidites to give phosphate intermediates which are reacted with sulfur in 2,6- lutidme to give phosphate compounds. Oligonucleotide compounds are prepared by treating the phosphate compounds with thiophenoxide (1:2:2
thiophenol/triethylamine/tetra-hydrofuran, room temperature, 1 hour) . The reaction sequence is repeated until an oligonucleotide compound of the desired length has been prepared (Formula 1) . The Formula I compounds are cleaved from the support by treating with ammonium hydroxide at room temperature for 1 hour and then are further deprotected by heating at about 50°C overnight to yield Formula I compounds. Formula I compounds m which at least one X is oxygen are prepared by substituting I2- H20 for the sulfur in 2,6-lutιdme.
Formula I compounds in which at least X is CH3 or other Cj 4 alkyl are prepared by the following published procedure: K.L. Aqarwal and F. Riftma, 6 Nucl . Acids Res. 3009-3023 (1979) . The reaction sequence is conducted on a solid support. The reaction procedure involves phosphorylation of the 3'-hydroxyl group of a 5' -protected nucleoside using methylphosphonoditriazolide as the phosphorylatmg reagent followed by benzene sulfonyl-catalyzed coupling of the methylphosphonates to yield the methyl phosphonate oligonucleotide.
Methylphosphonoditriazolide is prepared m situ from equimolar quantities of methylphosphono-dichloridate, triethylamme, and triazole. Benzene sulfonyl tetrazole also was prepared m situ from pyrid e, benezene sulfonic acid and triethylamme. Repeating this reaction sequence followed by cleavage from the support and deprotection yield Formula I compounds.
Formula I compounds in which R is Cx 4 alkyl are prepared by replacing the DMT-protected compounds with Cj 4 alkylethers.
Formula I compounds in which R is P(0) (0) - substituted acridme also are prepared by the following published procedures. U. Assel e and N.T. Thuong, 30(19) Tet . Letters 2521-2524 (1989) CA. Stem, et. al . , 72 Gene 333-341 (1988) . These published procedures include synthesis of a nucleoside phosphoramidite-bearmg
acπdme derivative which then is reacted with 2, 2'- dithiodiethanol attached to a support. The elongation chain then is carried out on an automatic solid-phase DNA synthesized as described above. These published procedures also include synthesis of nucleoside phosphoramidite-bearmg acridme derivatives by reacting substituted 9- (3-hydroxypropyl) amino acridmes with N- ethyldiisopropylamme followed by N,N- diisopropylmethylphosphonamidic chloride. Using an automated DNA synthesizer, Formula I compounds in which R is P(0) (0) -substituted acridme are prepared by an extra round of synthesis using the acπdinyl phosphoramidites in acetonitrile.
The compounds of Formula I can be incorporated into convenient pharmaceutical dosage forms such as capsules, tablets, or mjectable preparations. Solid or liquid pharmaceutical carriers can be employed. Solid carriers mclude starch, lacrose, calcium sulfate dehydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Liquid carriers mclude syrup, peanut oil, olive oil, saline and water. Liposomal, viral vector, and prote conjugate preparations can also be used as carriers. Similarly, the carrier or diluent may include any prolonged release material, such as glyceryl monosteararate of glyceryl disteararate, alone or with a wax. The amount of solid carrier varies widely but, preferably, will be from about 25 mg to about 1 g per dosage unit. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile mjectable liquid such as an ampoule, or an aqueous or nonaqueous liquid suspension. When a liquid carrier is used it will most often be a saline solution or phosphate buffered saline solution. The pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist
mvolv g mixing, granulating and compressing, when necessary, for tablet forms, or mixing, filling, and dissolving the ingredients, as appropriate, to give the desired oral or parenteral products. Doses of the present Formula I compounds ( a pharmaceutical dosage unit as described above) will be an efficacious, nontoxic quantity selected from the range of 1 ng/kg to 500 mg/kg of active compound, preferably less than 1 mg/kg. The selected dose is administered to a human patient in need of inhibition of AGT expression from 1-6 or more times daily, orally, rectally, by injection, or continuously by infusion. Oral formulations would generally require somewhat larger dosages to overcome the effects of gastric decomposition. Intravenous or mtraarterial administration would generally require minimum doses since the drug is placed directly into the systemic circulation. Therefore, the dose will depend on the actual route of administration. By peripheral administration we mean by any other route of delivery apart from oral or central (into the brain) . Peripherally administering the oligonucleotide compounds of the present invention via an artery (carotid) , vein (tail vein in rats or arm vein m humans) , or mtrapeπtoneally (m mammals) allows delivery to the liver without nav g to surgically open the abdominal cavity for injection mto the hepatic vein or artery as in Tomita, _t al.. , supra.
The following Examples are illustrative of Formula (I) compounds and their preparation. The Examples are not intended to limit the scope of the invention as defined above and claimed below.
This invention relates to an oligonucleotide compound which binds to a region of angiotensinogen mRNA preventing the production of angiotensinogen protem which is involved m the development and maintenance of hypertensive blood pressure. By encapsulating the
antisense molecules -in pharmaceutical carriers, such as liposomes, it is possible to obtain compositions which can be used in a method to target the delivery of the antisense molecules directly to the liver, the major site of angiotensinogen production in the body. Liver targeting can also be accomplished by packaging the antisense molecules with viral vectors and protein conjugates .
The compounds and compositions of the present invention are unique because there is no commercially available agent which specifically inhibits the action of angiotensinogen. Additionally, due to the chemical nature of antisense molecules the action is highly specific, allowing the administration of small doses, with potentially fewer side effects than conventional antihypertensive agents.
The liposome encapsulated oligonucleotide compounds of the present invention were demonstrated using an antisense oligodeoxynucleotide for inhibiting the angiotensinogen mRNA of spontaneously hypertensive rats. The sequence for rat mRNA is disclosed in Fig. 3 of Ohkubo, e al . , 80 PNAS USA 2196-2200 (1983) . One version of the invention is an 18 base oligomer, synthesized to complement the -5 to +13 base region of rat angiotensinogen mRNA, which encompasses the AUG translation initiation codon, the oligomer being composed of the following base sequence: 5' -CCGTGGGAGT CATCACGG-3' (SEQ ID NO:2) . A phosphorothioated backbone modification can be included on every base to confer nuclease resistance.
The compositions of the present invention comprise novel DNA sequences capable of binding to angiotensinogen mRNA, preferably encapsulated in a pharmaceutical delivery system, which results in the ASODN being delivered directly to the liver, the major site of angiotensinogen production. No viral antigen
modification of the antisense oligonucleotide is necessary.
Liposomes (80% phosphatidylcholme, 20% cholesterol) are prepared using a rotary evaporator apparatus for drying and rehydration of the lipid film. The liposomes are subjected to multiple freeze thaw cycles which enhances the entrapment of the antisense molecules and are then passed through an extruder (0.1 μm filter) m order to reduce their size. Size can then be determined by dynamic light scattering. For further details on various methods of making liposome-encapsulated biologically active compounds see U.S. patents 4,311,712; 4,370,349; 4,963,362; 5,264,221; 5,417,978; and 5,422, 120. As well as facilitating peripheral delivery, liposomal encapsulation facilitates cellular uptake of the antisense molecules resulting in an increased efficiency of delivery. This has allowed us to administer the antisense composition peripherally mto the blood stream and obtain physiological responses with doses which produced no physiological response when previously tested (see Gyurko, et al . , and Wielbo, et al . , supra) . Once the antisense molecule enters the cells it binds to the targeted region of angiotensinogen mRNA forming an mRNA/DNA duplex. This duplex formation serves to prevent the assembly of ribosomal sub units and the subsequent reading of the protem message, thereby inhibiting angiotensinogen production. The phosphorothioated form of the antisense molecule has enhanced nuclease resistance and additionally stimulates the action of RNase H, an enzyme which cleaves the mRNA portion of the duplex, subsequently freeing the antisense molecule to bind to another target mRNA.
We have shown that hypertensive blood pressure m animal models of hypertension can be decreased with a single, mtra-arterial dose of a composition comprising a
liposo e encapsulated antisense DNA fragment targeted to angiotensinogen. As well as being able to elicit a physiological response we also have been able to produce biochemical data which shows a subsequent decrease m angiotens II m the periphery at the time of blood pressure decreases. Our previous studies have also shown that a single dose of the antisense molecule into the brain of hypertensive animals will also decrease blood pressures for up to seven days. We have previously shown that a single 50 μg dose of antisense oligonucleotide targeted to angiotensinogen mRNA, administered directly mto the brains of spontaneously hypertensive rats resulted in a significant and profound decrease in hypertensive blood pressures for extended periods of time. The following figures demonstrate the physiological effects of the liposome encapsulated antisense molecules targeted to angiotensinogen in the liver of hypertensive rats.
An alternative delivery system that can be used is a viral vector. Fig. 6 shows the effect of a viral vector antisense delivery system on angiotensm II type 1 receptor expression in a neuroma-glioma brain tumor cell line. In this study, antisense (the entire length of the protem sequence) was targeted to the mRNA of the angiotensm II type 1 receptor. Cells were either treated with transfectam--an agent available to enhance the uptake of the viral vector; an empty, mock plasmid viral vector; paAT, the adeno-associated virus (AAV) vector containing the antisense sequence; and paAT + Ad, the adeno-associated viral vector containing the antisense and a helper virus for adeno-associated virus which enhances the AAV's p40 promoter which drives the expression of the antisense mRNA. Substantially less receptor binding was observed m the paAT + Ad treated cells. This indicates that mRNA expression is attenuated with the paAT + Ad treatment.
Another delivery system which can be used in the present invention is a protem conjugate oligonucleotide composition. This technique is based on the construction of DNA-protem complexes that are recognized by the liver specific asialoglycoprote receptor. Binding of polyd- lysme) -asialoorosomucoid (ASoR) protem conjugates with phosphorothioated antisense can facilitate cellular uptake m the liver. The conjugates use receptor mediated endocytotic mechanisms for delivering genes mto cells. By covalently linking a specific receptor ligand, such as asialoorosomucoid or transferrm to the polylysine to form DNA protem complexes, it has been possible to target cell specific surface receptors and transfix antisense DNA mto cells. See Bunnell, et. al . , 18 Somatic Cell Molec . Gen. 559-569 (1992) .
Example 1
Fig. 1 demonstrates the specificity of the target antisense molecule (SEQ ID NO:2) to the chosen target, the rat protein angiotensinogen. In these experiments, transcription and translation of the target protem was carried out m vi tro, utilizing complimentary DNA (cDNA) to angiotensinogen. The m vi tro reactions were carried out in the presence and absence of antisense molecules and scrambled or sense control oligonucleotide molecules. These m vi tro reactions can also be employed to evaluate the ability of the oligonucleotides of the present invention to inhibit expression of human angiotensinogen.
Data is presented as percent expression of angiotensinogen compared to the control reaction. Dose response studies were carried out encompassing a range of
30 μM oligonucleotide to 0.3 μM oligonucleotide. At higher doses of antisense, 3-30 μM, the expression of angiotensinogen was decreased to approximately 5-10% of the control. However, non-specific attenuation of angiotensinogen expression was observed with the
scrambled and sense oligonucleotides, a phenomenon recently described in the literature. In this regard, m Tomita, supra, the degree of response seen with doses of 15μMol/L is most likely due to this phenomenon. At lower doses of oligonucleotides, 0.3-1 μM, reactions carried out in the presence of antisense show profound attenuation of angiotensinogen production (45%) , with no observed non-specific attenuation with the scrambled oligonucleotide. This suggests that, at low doses, the antisense oligodeoxynucleotide profoundly and specifically attenuates the translation of angiotensinogen in vi tro .
Example 2
Figs. 2a and 2b show two confocal micrographs of rat liver tissue, one hour after injection of 50 μg of (a) unencapsulated, fluorescently labeled antisense (SEQ ID NO:2) , or (b) liposome encapsulated fluorescently labeled antisense (SEQ ID NO:2) directly mto the carotid artery. Micrograph (a) shows little or no distribution of fluorescent signal within the liver tissue. Micrograph (b) shows an intense and evenly distributed fluorescent signal throughout the tissue, indicating that liposome encapsulation facilitates the delivery of the antisense to the target organ. To demonstrate the physiological responses to traarterially, peripherally administered compositions comprising liposome encapsulated mRNA, antisense oligonucleotide targeted to liver angiotensinogen mRNA, groups of male, spontaneously hypertensive rats (250- 275 g) were catheterized via the carotid artery and allowed 24 hours to recover from surgery. Baseline mean arterial pressure (MAP) was then measured via direct blood pressure transducer, attached to the indwelling arterial catheter. A single 50 μg dose of either a composition comprising liposome encapsulated (25 g
lipid) antisense oligonucleotide (AS/L) , or liposome encapsulated scrambled oligonucleotide (Scr/L) , or empty liposomes (25 mg lipid) (Lipo) , or 50 μg unencapsulated antisense oligonucleotide (ASODN) was administered via the carotid artery. 24 hours later, mean arterial pressure was measured to determine blood pressure changes.
Example 3
This example demonstrates the effect of liposome encapsulated ASODN (SEQ ID NO:2) on mean arterial pressure (MAP) in spontaneously hypertensive rats. Baseline MAP was established in groups of rats. Then 50 μg of liposome encapsulated (25 mg lipid) ASODN (AS/L) ; liposome encapsulated ScrODN (Scr/L) ; empty liposomes (25 mg) (Lipo) ; or 50 μg unencapsulated ASODN was administered mtra-arterially. Fig. 3 shows the blood pressure changes observed 24 hours after each treatmen . Mean arterial pressure was significantly decreased in the group treated with liposome encapsulated antisense composition, (-24.66 mmHg ± 2.43) . However, no significant blood pressure changes were observed in the Scr/L (1.34 mmHg ± 3.98) ; Lipo (-5.34 mmHg ± 3.71) or ASODN (-6.02 mmHg ± 8.68) treatment groups. Results are expressed as Mean + SEM, P < 0.013, n=6 per group. This data supports the concept that peripherally administered compositions comprising the liposome encapsulated antisense (AS/L) will decrease hypertensive blood pressures in the SHR model of hypertension (which is predictive of what will occur in humans) . To determine biochemical changes, groups of animals
(n=3/group) were sacrificed 24 hours after treatment and plasma angiotensm II levels were measured by radioimmunoassay. Fig. 4 shows the effect of liposome encapsulated antisense (AS/L) treatment on plasma angiotensm II levels 24 hours after administration.
Example 4
This example demonstrates the effect of liposome encapsulated ASODN (SEQ ID NO:2) on angiotensin II. Animals were sacrificed 24 hours after treatment. Plasma angiotensin II levels were measured by radioimmunoassay. As shown in Fig. 4, angiotensinogen II was significantly lower in liposome encapsulated ASODN (AS/L) treated rats (30.3 + 11.4 pg/mL, n=5) compared to controls: liposome encapsulated ScrODN (Scr/L) (103.1 ± 33.2 pg/mL, n=3) ; empty liposomes (Lipo) (233.5 ± 71.1 pg/mL, n=3) ; and unencapsulated ASODN (201.4 ± 88.5 pg/mL, n=3), P<0.05. This data suggest that the antisense effects are mediated via the proposed mechanism of action, attenuating angiotensinogen production with a subsequent decrease in plasma angiotensin II.
Example 5
This example demonstrates the effect of liposome encapsulated ASODN (SEQ ID NO:2) on plasma AGT. Animals were sacrificed 24 hours after treatment and plasma AGT levels were measured by radioimmunoassay. As shown in
Fig. 5, AGT was significantly lower in liposome encapsulated ASODN (AS/L) treated rats (58.5 ± 3.71 pg/mL, n=5) compared to controls: liposome encapsulated ScrODN (Scr/L) (79.0 ± 8.72 pg/mL, n=3) ; empty liposomes (Lipo) (85 + 5.72 pg/mL, n=3) ; and unencapsulated ASODN (77.8 ± 3.25 pg/mL, n=3) , P<0.05.
Liposomes are drug vesicles in which an aqueous phase is enclosed in a membrane of phospholipid molecules, which form spontaneously when the lipids are dispersed in an aqueous medium. These vesicles range in size from nanometers to microns, and can be constructed to entrap quantities of materials in both the aqueous compartment and within the membrane. Advances in targeted drug delivery now enable liposomal encapsulation
of drug molecules to improve protection, sustained release and more efficient cellular uptake. Phosphatidylcholme liposomes have been shown to be efficient carriers of oligonucleotides, increasing efficiency of cellular uptake and also increasing the stability of the oligonucleotides in culture medium.
Cationic liposomes have been shown to be especially efficient in cellular uptake, due to complexmg of the negatively charged oligonucleotides on the liposome surface via electrostatic interactions (Ahktar, S. and
Juliano, R. L., Trends m Cell Biology 2:139-144, 1992) . In this study we use an AGT-secretmg Hepatoma cell line to test the hypothesis that a single 18 mer AGT antisense oligonucleotide conjugated to cationic liposomes will enhance its delivery and cellular uptake and thereby inhibit angiotensinogen production at lower doses and in a dose dependant manner. In previous studies, although we successfully decreased target protem production in vi tro and in vivo at high doses of naked ASODN, we did not observe decreases in target mRNA, thus leaving doubt as to the mechanism and specificity of protem inhibition.
Materials and Methods (Examples 6-9)
Antisense Synthesis: Using the AGT sequence established by Ohkubo
(Ohkubo, H., et al. Proc . Na tl . Acad . Sci . USA 80:2196- 200, 1983) , an 18 mer ASODN strand was synthesized to the -5 to +13 base sequence of the angiotensinogen mRNA, 5- CCGTGGGAGTCATCACGG-3 ' (SEQ ID NO: 2) . This region covers the AUG translation initiation codon. Control scrambled ODN (ScrODN) had the same base composition as the ASODN strand but m random order. These oligonucleotides are modified by phosphorotioation. ODNs were synthesized m the DNA Synthesis Laboratory, University of Florida. All
oligonucleotide sequences were surveyed via the National Center for Biotechnology Information BLAST network server and Genebank data program for homology with related proteins.
Liposome Synthesis:
Cationic liposomes composed of dimethyldiactadecylamonium bromide (DDAB) and dioleoylphosphatidylethanolamme (DPOE) (2:5, w/w) (Avanti Polar Lipids Inc., Alabaster, Alabama) were dissolved in 30 mL chloroform and the solvent evaporated by heating at 55°C under partial vacuum. Liposomes were prepared by resuspendmg the lipids m 1 mL sterile deionized water and somcation on ice until the solution was almost clear. ASODN or ScrODN were then added to give a concentration of 1 uM. The -/+ charge ratios of ODS/cationic lipids was 0.18, giving a net positive charge to the ODN-liposome conjugates to allow fusion between the cell membranes and ODN-liposome conjugates. For dose response studies five different oligonucleotide concentrations were prepared with different concentrations of DDAB to make ODN/cationic lipid complexes with the same-/+ charge ratios.
Cell Culture:
H-4-II E, Hepatoma, Reuber H35, rat cells were purchased from ATCC (Rockville, Maryland) . Cells were grown m monolayer culture in 12 mL of Eagles Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum, 10% calf serum and mcubated m 95% air - 5% C02 at 37°C. Cultures were fed everyday and passaged when confluent at a ratio of 1:6 usmg 1.0 mL of 0.25% tryps -EDTA. Cells were grown on 10 cm petπ dishes until experimentation. Cultures were then washed with EMEM to remove any serum supplemented media and then treated with varying concentrations of oligonucleotides
or liposome complexed oligonucleotides and control treatments.
Angiotensinogen Assay:
500 μl aliquots of culture medium were evaporated to dryness . The dried samples were assayed for angiotensinogen by the direct radioimmunoassay method of Serma (Sernia, C, et al.. , Neuroendocrmology 55:308- 316, 1992) . AGT sample content was measured from a standard curve of pure rat AGT diluted in the same cell culture medium as the medium as the sample. The assay sensitivity was 0.3 ng/tube, and an ter-assay and intra-assay variability of 14% and 9% respectively.
Northern blot:
Northern blot analysis was carried by the method of Chomczynski and Sacchi (Chomczynski, P. and Sacchi, N., Anal. Biochem . 162:156-9, 1987) and quantified by densitometric methods. Cells were lysed using mercaptoethanol then RNA was extracted by treatment with guanidium thiocyanate followed by phenol-chloroform extraction. RNA was precipitated by isopropanol at - 20°C. After centrifugation the amount of RNA was calculated by spectrophotometry. 20 μg aliquots of RNA were electrophoresed on an agarose formaldehyde gel at 25 V for 16 hours. Adequate separation of mRNA was observed using an RNA ladder and ethidium bromide staining. RNA was transferred to a nylon membrane by Northern blot, after prehybridization for 4 hours at 56°C with 1 x Denhardts SSPE solution, 5 x SSPE, 0.1% SDS and 50% formamide. The solution also contamed 250 mg/mL denatured salmon sperm DNA. Hybridization was carried out under the same conditions with a labeled riboprobe to the specific mRNA sequences. After wash steps the membrane was exposed to x-ray film then developed.
Membranes were standardized by reprobmg for Cathepsm D mRNA.
Statistical Analysis:
Statistical analysis was performed by ANOVA for treatment effect and Duncan multiple range test was used for individual comparisons. Radioimmunoassay data for individual time points was analyzed by students independent T-test. P<0.05 is considered statistically significant.
Determination of in vitro effects of ASODN on angiotensinogen production and angiotensinogen mRNA expression in Hepatoma H4 cell culture.
H4 Hepatoma cell cultures were grown to confluence then treated with cationic liposome conjugated ASODN and ScrODN (1 μM) or 1 μM naked ASODN or cationic lipid control solutions. Cultures were mcubated for 24 hours. Media was decanted and after 100 μl aliquots were collected for AGT assay, cells were recovered from the petri dishes. Combing two treatment plates to ensure sufficient cells, mRNA was extracted and analyzed by Northern blot to determine AGT mRNA levels. Northern blots were quantified by densitometry. Media aliquots were lyophilized and assayed for AGT levels by RIA. Six, 100 mm plates were combined for each sample assay.
Dose response relationships of cationic liposome conjugated ASODN in Hepatoma H4 cell culture.
H4 Hepatoma cell cultures were grown to confluence then treated with cationic liposome complexed ASODN at the following concentrations: 0, 0.01, 0.05, 0.1, 0.5 and 1.0 μM. Control groups consisted of increasing amounts of cationic lipid in amounts necessary to maintain an ASODN lipid ratio of -/+. ODN/cationic lipid, 0.18. Cultures were cubated for 24 hours.
Media was decanted and 100 μl aliquots were lyophilized and assayed for AGT levels by RIA. Cells were recovered from petri dishes after collection of the media, combining two treatment plates to ensure sufficient cells, mRNA was extracted and analyzed by Northern blot analysis to determine ASODN dose effects on AGT mRNA. Northern blots were quantified by densitometπc methods.
Example 6
To determine the effect of cationic liposome complexed ASODN and control treatments on mRNA expression cell cultures were treated with 1 μM of cationic liposome complexed ASODN, complexed ScrODN, cationic liposomes and 1 μM naked ASODN. Fig. 7a shows the result of Northern hybridization for AGT (1.9 Kb) and the control gene cathepsm (2.1 Kb) . Samples 1-5 correspond to the following treatments: 1. Naked antisense (ASODN) ; 2. Empty cationic liposome control (CL) ; 3. Cationic liposome complexed ScrODN control (Scr/CL) ; 4. Cationic liposome complexed ASODN (AS/CL) and 5. Non-treated control (CTRL) . Fig. 7b corresponds to the relative intensity of AGT mRNA expression after treatment compared to AGT expression in untreated control cells. Expression is presented as percent control. Cells treated with naked ASODN (ASODN) appeared to have AGT expression attenuated to 70%. Control treatments of uncomplexed liposomes (CL) and liposome complexed ScrODN (Scr/CL) resulted in little change from baseline levels with approximately 90% expression. However, cells treated with liposome complexed ASODN (AS/CL) only show 22% expression.
Example 7
To determine the effect of ASODN on AGT production in Hepatoma H4 cell culture, cell cultures were treated as before and culture media was analyzed for AGT protein
levels using RIA. Fig. 8 shows the amount of AGT produced by Hepatoma cell culture after control and ASODN treatments. This graphs shows the effect of cationic liposome complexed ASODN on AGT production. Cells were incubated with 1 μM of ASODN in the presence or absence of cationic liposomes and appropriate controls. In untreated controls (CTRL) the baseline AGT level was 52.0±2.46 ng/mL. There was no significant decrease in AGT production from baseline levels in the empty liposome (CL) and liposome complexed ScrODN (Scr/CL) control groups (45.53±5.9; 47.03+6.9 ng/mL; n=3 , respectively) . Cells treated with naked ASODN and cationic liposome complexed ASODN (AS/CL) had AGT levels significants decreased from baseline levels (30.2+3.0 ng/mL, n=3 , *=P≤0.05 and 5.61±.95 ng/mL; n=3, **=p≤0.01, respectively) .
Example 8
Dose response relationships of cationic liposome complexed ASODN in Hepatoma H4 cell culture were then conducted. Fig. 9a and 9b show a dose dependant attenuation of AGT mRNA using cationic liposomes as delivery mechanisms. Fig. 9a shows the result of Northern hybridization for AGT and the control gene cathepsm D. Samples 1-5 shows representative blots of cells treated with only cationic liposomes. Each oligonucleotide concentration was accompanied by a separate control of uncomplexed liposomes as the concentration of liposome per treatment increased proportionally with each increase in oligonucleotide concentration. Samples 6-10 correspond to cells treated with 0.01, 0.05, 0.1, 0.5 and 1.0 μM cationic liposome complexed ASODN. Sample 11 shows AGT mRNA expression in untreated control cells, which is used as the baseline expression of AGT for the comparison of attenuation after test ASODN treatments. Fig. 9b graphs the relative
expression of the mRNA compared to the control treated samples. The average expression for cells treated with control cationic liposomes was 92%. Cells treated with 0.01 and 0.05 μM ASODN had approximately 92% expression which was similar to the control cationic liposome treatments. At higher doses of ASODN, at 0.1, 0.5 and 1 μM the expression was decreased in a dose dependant manner to 60%, 56% and 24% of control expression, respectively. No changes were observed m the expression of the Cathepsm D mRNA after each treatment.
Example 9
Fig. 10 shows dose dependant decreases in AGT protem after cationic liposomal delivery of ASODN. Again each oligonucleotide concentration was accompanied by a separate control of uncomplexed liposomes as the concentration of liposome per treatment increased proportionally with each increase in oligonucleotide concentration. The baseline level of AGT protem was 51.77±3.7 ng/mL in the untreated controls (n=3) . No changes in baseline AGT production were observed using empty cationic liposomes, mean AGT levels were 48.5 ng/mL for each increasing dose. Consistent with decreases in mRNA levels, no significant decreases in AGT were observed with lower doses of ASODN (0.01 μM or 0.05 μM) AGT protem levels were 47.6+7.4 and 40.29±4.0 ng/mL, respectively, although a decreasing trend is apparent. At 0.1, 0.5 and 0.1 μM ASODN the protein levels were significantly decreased from baseline levels m a dose dependant manner. AGT protem levels were 26.86±5.3; 23.27±6.1 and 5.67±0.3 ng/mL, n=3 per group; *=p≤0.05 and **=P≤0.01.
Discussion of Examples 6-9
Although successful target protein attenuation has been achieved using antisense technology m a wide range
of biological systems, the development of antisense therapy has not been as smooth as once anticipated. Problems have been encountered in the delivery of the molecules to the target site. Cellular uptake of ASODN molecules is thought to be via specific receptor interaction or via receptor mediated endocytosis (Morishita, R. , et. al. , supra, 1993; Loke, S. L., et. al . , Proc . Natl . Acad . Sci . USA 86:3474-3478, 1989; Temsamani, J., et. al . , Antisense Research and Development 4:35-42, 1994; Wickstrom, E., Trends -Biotechnol . , 10(8) :281-7,
1992) , but in general uptake efficiency is poor with as little as 2% of ASODN entering the cells and as few as 1% of cells being transfected (Ahktar, S. and Juliano, R. L., supra, 1992) . The amount of naked oligonucleotides taken up by viable cells ranges from 1-10% with the rate of transfection being variable between cell types. Liposomal delivery systems have been shown to facilitate and increase the efficiency of cellular uptake of ASODN, by protecting the antisense from degradation and by bringing the antisense molecules into closer proximity to the cells thereby facilitating the uptake process. In particular, cationic liposomes have been shown to increase uptake efficiency by 30% (Lappalainen, K. , et, al . , Biochimica et Biophysica Acta 1196:201-208, 1994) . Consequently due to the expected enhanced delivery and cellular transfection of cationic liposomes we expected that AGT protein and mRNA levels would be decreased accordingly.
The above data suggests that cationic liposomes are efficient delivery systems for an antisense molecule targeted to angiotensinogen mRNA. Our data shows that at 1 μM doses, liposome complexed ASODN specifically decreases target protein and mRNA more profoundly than naked ASODN alone. These observations can be attributed to the specific inhibition of target mRNA as no significant decreases m target protein were observed
with liposome complexed ScrODN or control cationic lipids. Furthermore, the same dose of liposome complexed ASODN also resulted m significant decreases m target mRNA from baseline levels. This suggests that the mode of oligonucleotide action may be through the stimulation of RNase H. This enzyme recognizes the mRNA-DNA double- strand as a substrate and subsequently degrades the mRNA portion of the duplex. Hence the observed decrease m angiotensinogen mRNA although this particular oligonucleotide was designed to inhibit translational processes and ribosome binding at the AUG initiation codon.
Interestingly, although mRNA expression was less than baseline levels (but not significantly) after naked ASODN treatment, we observed that naked ASODN did significantly decrease AGT prote levels, although not as profoundly as the cationic liposome complexed ASODN. This observation is probably due to the cationic liposomes resulting in an increase m oligonucleotide delivery due to the negatively charged oligonucleotide and the cationic charge of the lipids resulting in a substantial amount of liposome/oligonucleotide surface binding.
We conclude that efficient cellular delivery of antisense oligonucleotides is an important consideration in obtaining efficacy of protem attenuation and that such delivery may be facilitated through the use of liposomal delivery systems. Cationic liposomes may be utilized to substantially increase the delivery efficiency of oligonucleotides m cell culture to the extent that intracellular ASODN levels elicit both attenuation of target protem and target mRNA. This delivery system offers a simple approach for the determination of basic ASODN properties, enablmg sufficient mtracellular levels of ASODN for activity
without the need for viral vector delivery or targeted cellular delivery.
Example 10
In this study, baby SH rats which are normotensive until about 8 weeks of age, were injected with a single dose (50μg oligo) of liposome encapsulated oligonucleotide (the base sequence of the oligonucleotide being in accordance with SEQ ID NO: 2) via the tail vein, once a week for four weeks. This was done after weaning from age 4 weeks to 8 weeks.
At 8, 12, and 18 weeks their blood pressure was measured indirectly, usmg the tail cuff method. At 8 weeks of age the liposome antisense treated rats had blood pressures at 126.2 mm Hg ± 7.49. This was significantly lower than the control treatment groups (P<0.05) . This lowering of blood pressure maintained pressures the normotensive range whereas the control groups had blood pressures in the hypertensive range. At 12 weeks of age, 8 weeks after the final ASODN-liposome treatment, animals still had lower blood pressures compared to the control treatment group. Although this lowered blood pressure was not significantly lower than the control groups and was still in the hypertensive range, a trend was evident and significance could probably be achieved by increasing the sample size. At
18 weeks of age all groups of rats had blood pressures m the hypertensive range.
Thus, administration of liposome encapsulated antisense during the critical growth phase of baby rats can transiently, but significantly attenuate the development of hypertension. The duration of this attenuation could possibly be extended by increasing dosing frequency or amount of ASODN. That attenuation can be achieved by simple venous administration without the need for invasive surgery.
Although the present invention has been described with reference to certain preferred embodiments, other variants are possible. For example, the present invention includes oligonucleotide compounds which lack a complement for each nucleotide in a particular segment of the angiotensinogen mRNA, provided such compounds have sufficient binding affinity for the AGT mRNA to inhibit expression thereof. In this regard, the materials and methods of Examples 6-9, supra, are useful m determmmg whether specific oligonucleotides are effective in inhibiting angiotensinogen expression. Obviously, the above methods would be modified when evaluating specific compounds for the inhibition of human angiotensinogen. For example, human cells such as human embryonic cell lines or human hepotoma cell lines could be used for the cell culture. Also, the present mvention is intended to mclude mixtures of oligonucleotide compounds, each compound being capable of binding to angiotensinogen mRNA. Therefore, the scope of the claims is not limited to the specific examples of the preferred versions herein. Rather, the claims should be looked to m order to judge the full scope of the invention.
Industrial Applicability The oligonucleotides disclosed herein are useful for inhibiting the expression of angiotensinogen to thereby control angiotensinogen induced hypertension.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(l) APPLICANT:
(A) NAME: University of Florida
(B) STREET: Box 115500
(C) CITY: Gainsville
(D) STATE: Florida
(E) COUNTRY: United States of America
(F) POSTAL CODE: 32611-5500
(G) TELEPHONE: (352) 392-8929 (H) TELEFAX: (352) 392-6600
(ll) TITLE OF INVENTION: OLIGONUCLEOTIDES TARGETED TO
ANGIOTENSINOGEN mRNA
(iii) NUMBER OF SEQUENCES: 2
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Quarles & Brady
(B) STREET: 222 Lakeview Avenue, P.O. Box 3188
(C) CITY: West Palm Beach
(D) STATE: Florida
(E) COUNTRY: U.S.A.
(F) ZIP: 33402-3188
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vm) ATTORNEY/AGENT INFORMATION:
(A) NAME: Nelson, Gregory A.
(B) REGISTRATION NUMBER: 30,577
(C) REFERENCE/DOCKET NUMBER: 5853-23
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (561) 653-5135
(B) TELEFAX: (561) 653-5333
(2) INFORMATION FOR SEQ ID NO:l:
(l) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(n) MOLECULE TYPE: Other nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CTCGCTTCCG CATACCCT 18
(2) INFORMATION FOR SEQ ID NO:2 :
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(11) MOLECULE TYPE: Other nucleic acid (XI) SEQUENCE DESCRIPTION: SEQ ID NO:2: CCGTGGGAGT CATCACGG 18
Claims (21)
1. An oligonucleotide represented by the formula:
wherein each X independently is 0, S, or C1_4 alkyl; each B independently is adenine, guanine, cytosine, or thymine selected such that the oligonucleotide binds to the sense mRNA strand coding for human angiotensinogen when present to thereby inhibit the translation thereof; each R independently is H or C2.4 alkyl or P(0) (0) -substituted acridine; each Y is independently H or OH; and n is 8 to 23.
2. A compound which is a pharmaceutically acceptable salt or hydrate of the oligonucleotide of claim 1.
3. The oligonucleotide of claim 1 m which B is selected such that the oligonucleotide is antisense to the sense mRNA strand coding for human angiotensinogen.
4. The oligonucleotide of claim 3 wherem B is selected such that the oligonucleotide binds to the mRNA base region encompassing the AUG initiation codon.
5. The oligonucleotide of claim 4 wherem B is selected such that the oligonucleotide binds to a region overlapping the mRNA -5 to +13 base region and encompassing the AUG initiation codon.
6. The oligonucleotide of claim 5 wherem B is selected such that the oligonucleotide binds to the mRNA -5 to +13 base region encompassing the AUG initiation codon.
7. The oligonucleotide of claim 5 wherem B is selected such that the base sequence of the oligonucleotide is according to SEQ ID NO: 1.
8. A pharmaceutical composition useful for inhibiting expression of angiotensinogen comprising a pharmaceutical carrier and the oligonucleotide of claim 1.
9. The pharmaceutical composition of claim 8 in which B is selected such that the oligonucleotide is antisense to the sense mRNA strand coding for human angiotensinogen.
10. The pharmaceutical composition of claim 9 wherem the pharmaceutical carrier is a liposome formulation.
11. The pharmaceutical composition of claim 10 wherein the liposome formulation is a cationic liposome formulation.
12. The pharmaceutical composition of claim 9 wherein the pharmaceutical carrier is a viral vector formulation.
13. The pharmaceutical composition of claim 9 wherein the pharmaceutical carrier is a protein conjugate formulation.
14. A method for treating hypertension in a human comprising: administering to a subject an effective amount of the oligonucleotide of claim 1.
15. The method of claim 14 in which B is selected such that the oligonucleotide is antisense to -the sense mRNA coding for human angiotensinogen.
16. A method for treating hypertension in a human comprising: administering to a subject an effective amount of the composition of claim 8.
17. A method for treating hypertension in a human comprising: administering to a subject an effective amount of the composition of claim 11.
18. A method for treating hypertension in a human comprising: administering to a subject an effective amount of the composition of claim 12.
19. A method for treating hypertension in a human comprising: administering to a subject an effective amount of the composition of claim 13.
20. A method for preventing hypertension in a human comprising: administering to a subject an effective amount of the composition of claim 8.
21. A method for preventing hypertension in a human comprising: administering to a subject an effective amount of the composition of claim 11.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61686096A | 1996-03-15 | 1996-03-15 | |
US08616860 | 1996-03-15 | ||
PCT/US1997/004019 WO1997033623A1 (en) | 1996-03-15 | 1997-03-14 | OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2529697A true AU2529697A (en) | 1997-10-01 |
Family
ID=24471266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU25296/97A Abandoned AU2529697A (en) | 1996-03-15 | 1997-03-14 | Oligonucleotides targeted to angiotensinogen mrna |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0906123A4 (en) |
JP (1) | JP2000506866A (en) |
AU (1) | AU2529697A (en) |
CA (1) | CA2248932A1 (en) |
WO (1) | WO1997033623A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015643A2 (en) * | 1997-09-25 | 1999-04-01 | University Of Florida | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE |
ES2773489T3 (en) | 2012-07-27 | 2020-07-13 | Ionis Pharmaceuticals Inc | Modulation of diseases related to the renin-angiotensin system (RAS) using angiotensinogens |
CN105143203A (en) | 2013-04-17 | 2015-12-09 | 辉瑞大药厂 | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
EP3960183A1 (en) | 2015-10-08 | 2022-03-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
KR20230108728A (en) | 2020-11-18 | 2023-07-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compounds and methods for modulating angiotensinogen expression |
CN113862268A (en) * | 2021-10-20 | 2021-12-31 | 厦门甘宝利生物医药有限公司 | AGT inhibitors and uses thereof |
KR20240103025A (en) * | 2021-11-16 | 2024-07-03 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | Compositions and methods for inhibiting expression of angiotensinogen (AGT) protein |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631237A (en) * | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
-
1997
- 1997-03-14 WO PCT/US1997/004019 patent/WO1997033623A1/en not_active Application Discontinuation
- 1997-03-14 EP EP97916760A patent/EP0906123A4/en not_active Withdrawn
- 1997-03-14 AU AU25296/97A patent/AU2529697A/en not_active Abandoned
- 1997-03-14 CA CA002248932A patent/CA2248932A1/en not_active Abandoned
- 1997-03-14 JP JP9532856A patent/JP2000506866A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2248932A1 (en) | 1997-09-18 |
EP0906123A1 (en) | 1999-04-07 |
WO1997033623A1 (en) | 1997-09-18 |
JP2000506866A (en) | 2000-06-06 |
EP0906123A4 (en) | 1999-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6849726B2 (en) | Non-nucleotide containing RNA | |
US6312900B1 (en) | Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 | |
Thierry et al. | Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity | |
US6040296A (en) | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation | |
US5989906A (en) | Method and reagent for inhibiting P-glycoprotein (mdr-1-gene) | |
JP3121599B2 (en) | Antisense oligonucleotide regulation of raf gene expression | |
EP0725788B1 (en) | 2'-amido and 2'-peptido modified oligonucleotides | |
US5821234A (en) | Inhibition of proliferation of vascular smooth muscle cell | |
US6365345B1 (en) | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role | |
JP3054745B2 (en) | Antisense oligonucleotide regulation of raf gene expression | |
US6025339A (en) | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation | |
IL194419A (en) | Dsrna for inhibiting the expression of human eg5 gene in a cell, a pharmaceutical composition comprising same, method and vector | |
WO1992000990A1 (en) | Interleukin receptor expression inhibiting antisense oligonucleotides | |
JP2000506382A (en) | Methoxyethoxy oligonucleotides for regulating protein kinase C expression | |
JP2003505517A (en) | Conjugates and methods for their preparation and their use for transporting molecules across biological membranes | |
AU2529697A (en) | Oligonucleotides targeted to angiotensinogen mrna | |
US20020102694A1 (en) | Nucleozymes with endonuclease activity | |
Tomita et al. | Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach | |
Wielbo et al. | Antisense inhibition of angiotensinogen in hepatoma cell culture is enhanced by cationic liposome delivery | |
JPH0851985A (en) | Olignonucleotide for suppressing expression of isoprenyl protein transferase,therapeutic agent composition containingthe same and method for use of said composition | |
CA2743828C (en) | Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells | |
US6087343A (en) | Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use | |
AU730934B2 (en) | Non-nucleotide containing enzymatic nucleic acid | |
AU1457195A (en) | Non-nucleotide containing enzymatic nucleic acid |